Form 8-K Verrica Pharmaceuticals For: Aug 14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Verrica Pharmaceuticals (VRCA) PT Lowered to $13 at RBC Capital
August 15, 2024 6:16 AM EDTRBC Capital analyst Daniel Busby lowered the price target on Verrica Pharmaceuticals (NASDAQ: VRCA) to $13.00 (from $14.00) while maintaining a Outperform rating.
The analyst comments "VRCA's 2Q report shows steady progress for YCANTH through its molluscum contagiosum launch as distribution network expands; although aspects such as... More
